Dr Jeffrey Weber on the Staging of Melanoma and Choosing Treatment Options

Source: AJMC, May 2022

Medical oncologist Jeffrey S. Weber, MD, PhD, spoke with The American Journal of Managed Care® (AJMC®) about how treatment options have improved for more advanced melanoma cases and the role that genetic mutations play in choosing therapy.

Jeffrey S. Weber, MD, PhD spoke with The American Journal of Managed Care® (AJMC®) about how treatment options have improved for more advanced melanoma cases and the role that genetic mutations play in choosing therapy. He is the deputy director and head of experimental therapeutics, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, in New York.

AJMC®: I’d like to start our conversation off talking about some baseline specifics about melanoma, in particular staging. How is this disease staged? Really, when we’re talking about more advanced melanomas like stage III and IV, what does it mean to have those levels of melano

READ THE ORIGINAL FULL ARTICLE